Skip to main content
Oncotarget logoLink to Oncotarget
. 2022 Aug 4;13:968–969. doi: 10.18632/oncotarget.28104

Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

Reza Bayat Mokhtari 1,2,3,, Bessi Qorri 3, Narges Baluch 4, Angelo Sparaneo 5, Federico Pio Fabrizio 5, Lucia Anna Muscarella 5, Albina Tyker 6, Sushil Kumar 7, Hai-Ling Margaret Cheng 8, Myron R Szewczuk 3,, Bikul Das 2,9,10, Herman Yeger 1,
PMCID: PMC9450989  PMID: 36093295

This article has been corrected: Due to errors in figure preparation, the AZ-treated (72 hr) images (row 1, panel 2), is an accidental duplicate of the ‘CTRL’ image in row 3, panel 1 of Figure 1A. The corrected Figure 1A, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 1.

Figure 1

(A) AZ, SFN, and the combination of AZ+SFN dose-dependently affect the ability for wound closure of typical H727 BC cells measured over 72 hours compared to untreated control cells using a scratch wound assay. (A) Pictures representative of two separate experiments (n = 2) performed in triplicates showing similar results.

Original article: Oncotarget. 2021; 12:1470–1489. 1470-1489. https://doi.org/10.18632/oncotarget.28011


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES